In addition to CB2 receptors, BCP also activates peroxisome proliferator-activated receptor α and γ (PPARα-γ) [22,23], making it suitable to interfere with several metabolic pathways and pathological conditions, including apoptotic, inflammatory, cholesterolemic and behavioral disorders. The gene discussed is PPARA; the disease is Atypical behavior.